Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joseph Scales

Urology Plano, TX Medical Doctor

NPI 1922449552 CMS profile 1288621

6124 W Parker Rd Ste 434, Plano, TX 75093

Open in the dashboard

General payments

$10,358

482 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joseph Scales of Plano, TX is reported in the CMS Open Payments database as having received $10,358 across 482 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,426 108
2024 General $2,481 84
2023 General $1,883 88
2022 General $1,591 89
2021 General $788 44
2020 General $363 22
2019 General $825 47

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joseph Scales
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Joseph Scales were reported at $2,426. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Joseph Scales Urology median Middle half National median
2019 $825 $480 $147–$1,201 $163
2020 $363 $246 $87–$645 $114
2021 $788 $358 $111–$1,000 $132
2022 $1,591 $476 $143–$1,263 $149
2023 $1,883 $560 $168–$1,461 $160
2024 $2,481 $563 $170–$1,464 $164
2025 $2,426 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Astellas Pharma US Inc $1,296 78 payments
  2. AbbVie, Inc. $817 53 payments
  3. Dendreon Pharmaceuticals LLC $813 35 payments
  4. Edap Technomed Inc $807 6 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $775 37 payments
  6. Janssen Biotech, Inc. $719 33 payments
  7. Sumitomo Pharma America, Inc. $550 24 payments
  8. Pfizer Inc. $339 17 payments
  9. Ferring Pharmaceuticals Inc. $304 12 payments
  10. Endo Pharmaceuticals Inc. $303 14 payments
  11. Other $3,635 173 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,984 475 payments
  2. Education $374 7 payments
Products named General payments · program years 2019–2025
  1. MYRBETRIQ $1,003 67 payments
  2. PROVENGE $813 35 payments
  3. Nubeqa $775 37 payments
  4. XTANDI $614 33 payments
  5. ERLEADA $610 28 payments
  6. ORGOVYX Hormone Therapy $465 20 payments
  7. XIAFLEX $441 20 payments
  8. LUPRON DEPOT $370 22 payments
  9. GEMTESA $347 21 payments
  10. ORGOVYX Oncology $323 16 payments
  11. Other $4,762 231 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 32 drugs

Part D claims

2,433

Median for Urology: 1,053

Drug cost

$1,115,252

Median for Urology: $101,464

Branded share of claims

30%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtandi Enzalutamide Brand 44 $609,174
Erleada Apalutamide Brand 12 $179,142
Orgovyx Relugolix Brand 61 $165,954
Myrbetriq Mirabegron Brand 112 $102,841
Solifenacin Succinate Generic 218 $10,445
Tamsulosin Hcl Generic 613 $8,051
Mirabegron Er Mirabegron Brand 14 $6,932
Oxybutynin Chloride Er Oxybutynin Chloride Brand 192 $4,993
Trospium Chloride Er Trospium Chloride Brand 16 $3,767
Clomid Clomiphene Citrate Brand 19 $3,163

The 10 drugs with the highest cost, of 32 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 94 billing codes

Paid by Medicare

$294,097

Of which drugs: $32,933

Medicare patients

774

Average age 76

Services billed

19,386

143 women, 631 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Ischemic heart disease 39%
Diabetes 32%
Chronic kidney disease 32%
Cancer 29%
Atrial fibrillation 21%
Depression 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Leuprolide acetate (for depot suspension), 7.5 mg J9217 Office 20 129 $18,251
Injection, garamycin, gentamicin, up to 80 mg J1580 Office 25 25 $44

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
PROVENGE
  • Dendreon Pharmaceuticals LLC $248
$248 — —
Nubeqa
  • Bayer HealthCare Pharmaceuticals Inc. $160
$160 — —
ADSTILADRIN
  • Ferring Pharmaceuticals Inc. $127
$127 — —
BOTOX
  • AbbVie, Inc. $117
$117 — —
ERLEADA
  • Janssen Biotech, Inc. $80
$80 12 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

482 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record